Addex Therapeutics Reports Increased Q1 Loss, Critically Low Cash, and Going Concern Warning
ADXN is trading near its 52-week low of $5.41 (11% above the low).
Summary
Addex Therapeutics disclosed a significant Q1 net loss, a critically low cash position with only one month of runway, and a going concern warning, alongside recent dilutive share sales.
Key Events · Earnings and Guidance · ADXN
-
Going Concern Warning Issued
The company's cash and cash equivalents are only sufficient to fund operations through July 2026, raising substantial doubt about its ability to continue as a going concern for the next year.
-
Increased Net Loss in Q1 2026
Net loss for Q1 2026 widened to CHF 1.7 million, an increase from CHF 1.5 million in Q1 2025.
-
Critically Low Cash Balance
Cash and cash equivalents decreased to CHF 0.9 million as of March 31, 2026, down significantly from CHF 2.8 million a year prior.
-
Ongoing Dilutive Share Sales
From April 1 to June 24, 2026, the company sold 6.46 million shares for gross proceeds of CHF 288,032, indicating continued reliance on equity financing to sustain operations.
Analysis · ADXN · Life Sciences
Addex Therapeutics reported a wider net loss for Q1 2026 and a critically low cash balance, raising substantial doubt about its ability to continue as a going concern beyond July 2026. The company has continued to sell shares post-quarter, indicating ongoing capital needs and further dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADXN was trading at $6.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $5.41 to $12.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.